Intralipid and IVIG After Failed IVF: Do Immune Infusions Improve Outcomes?

A failed embryo transfer can have many explanations, and often no single correctable cause is found. Terms such as 'high natural killer cells' or 'immune rejection' may be used loosely in advertising. The tests behind these labels do not necessarily predict an individual embryo's ability to implant. A patient should ask which test was performed, its validated reference range and how results connect to a treatment supported by evidence. Prior transfers also differ in embryo quality, maternal age, uterine assessment and medication preparation; those factors deserve a structured review.

Intralipid is a fat emulsion used medically for nutritional purposes. In fertility settings, it has been proposed to influence immune activity, but biological plausibility is not proof that it increases live birth. The UK fertility regulator's patient guidance states that moderate- or high-quality studies do not support claims of improved chances of having a baby with intralipid. It requires an intravenous line and clinical oversight. Potential reactions, infection and financial cost are relevant even if an advertised protocol sounds simple.

Intravenous immunoglobulin is a blood-derived product used for specific medical indications, not an ordinary IVF medicine. The HFEA warns against its use as a fertility add-on because evidence is inadequate and significant harms are possible. Depending on the person and preparation, infusion reactions and other serious complications can occur. A clinic should never describe it as an innocuous vitamin infusion. If someone has a genuine autoimmune or other medical condition, that diagnosis requires management by an appropriate specialist, separate from marketing an unproven implantation treatment.

Ask the fertility specialist for an embryo-by-embryo chronology, transfer details, uterine findings, hormone schedule, and explanations for any deviations from the plan. Confirm whether prior transfer attempts were actually comparable. A clinician may recommend targeted evaluation based on symptoms or specific history, but broad immunological panels should not be ordered without a reason. Obtain documentation distinguishing a treatment used for an established medical condition from a fertility add-on whose benefit is uncertain. This distinction helps patients avoid unnecessary therapy and confusing new test results.

Good consent describes uncertainty in plain language, alternative options, adverse events and total fees, including staff and infusion supplies. If an offered treatment has no convincing benefit, patients should be free to decline without being told they have abandoned their last chance. An independent specialist can examine whether a proposed intervention addresses a recognised diagnosis. Emotional pressure after IVF failure is understandable, but treatment decisions are stronger when they rely on data and patient priorities rather than a promise that immune infusions 'switch on implantation'.

HomeIVF and the limits of home-supported IVF. HomeIVF describes doctor-led fertility care that can coordinate treatment discussions and, when actually available and clinically suitable, selected home blood collection, injection assistance or teleconsultations. The purpose is fewer unnecessary clinic visits, not moving the IVF laboratory into the home. Follicle and lining scans may require visits to an imaging facility; egg retrieval, sperm preparation and embryology work, and embryo transfer remain facility-based. Even a familiar medicine or blood test may not be safe or appropriate for home delivery in every case. Availability, technique, timing and escalation routes must be checked with the responsible clinician before a cycle begins.

HomeIVF can facilitate a doctor-led second-opinion discussion using previous stimulation, embryology and transfer records. It should not present intralipid or IVIG as a routine home-support product. Intravenous immune treatments, if indicated for another medical diagnosis, demand specific supervision and are not equivalent to assisted IVF injections. Basic blood collection at home, where appropriate and actually available, cannot establish a causal immune diagnosis on its own.

Turn information into an individual plan. Ask the treating fertility specialist to separate confirmed findings from possibilities, and to specify which result would genuinely change the next decision. Request an itemised written estimate that distinguishes consultation, stimulation medicines, ultrasound monitoring, laboratory handling, anaesthesia, egg retrieval, freezing, storage, testing and transfer where applicable. Not every item is needed in every cycle; some are optional, and prices should not be assumed from a national headline. Record the emergency contact pathway, the next appointment and any symptoms that call for urgent in-person assessment. This avoids mistaking remote convenience for reduced clinical oversight.

Request a written list of the evidence behind any immune-panel result, the incremental cost of each infusion and the circumstances in which treatment would be stopped. Ask whether the provider can show rigorous evidence for live birth, rather than hormone changes or biochemical pregnancy alone. Also discuss whether the money might be better directed to standard follow-up or an independent records review. Do not sign up for an infusion programme before receiving the safety documentation and the clinician's rationale.